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BARRIERS TO HYDROXYUREA USE IN SICKLE CELL DISEASE: 




Purpose: Sickle cell disease (SCD) is an inherited blood disorder that affects the 
hemoglobin protein of red blood cells and has a significant impact on morbidity, 
mortality, and quality of life. Hydroxyurea has been FDA approved since 1998 as 
a disease-modifying therapy for SCD. However, hydroxyurea has not been 
optimally utilized for those with SCD. The purpose of this study was to evaluate 
reasons for hydroxyurea use, from the perspectives of providers, adults with 
SCD, and parents/caregivers of children with SCD, as well as perceived barriers 
to its use. We examined indications and reasons for being “on hydroxyurea,” 
defined by patients as currently taking hydroxyurea, and reported on pain 
frequency, perceptions of barriers, hydroxyurea adherence, and health care 
access for patients with SCD who were either on and not on hydroxyurea. 
Methods: We conducted a cross sectional analysis of data collected within the 
Pacific Sickle Cell Regional Collaborative (PSCRC), a consortium of nine 
western U.S. states. Individuals were eligible for this study if they 1) had a 
confirmed diagnosis of SCD, 2) were followed at one of the PSCRC sites, and 3) 
were eligible for hydroxyurea therapy. Parents/caregivers of children with SCD 
less than 18 years and adults with SCD 18 years and older completed a brief 
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survey about hydroxyurea use, indications, side effects, pain frequency, number 
of hospital and emergency department (ED) admissions per year, and individual 
and family perceptions of barriers to hydroxyurea use. Participants completed a 
follow-up survey annually, but we reported only on baseline data. Data collection 
occurred between February 2016 and May 2018. 
Results: Individuals with SCD (n = 413) included 1) children (n=178; 6.7 ± 3.4 
years), 2) adolescents (n=66; 15.0 ± 1.4 years), 3) young adults (n=57; 21.4 ± 
2.6 years), and 4) adults (n=112; 39.2 ± 10.6 years). The majority were 
predominantly female (51.6%), African American (93.2%), and had HgbSS 
(74.1%) genotype. The majority of children (65.2%), adolescents (62.1%), and 
young adults (54.4%) were on hydroxyurea; fewer adults (39.3%) were on 
hydroxyurea. The majority with HgbSS (65.5%) were adherent to hydroxyurea. 
There was no significant difference in hospitalizations for pain, ED visits, and 
pain severity in the previous 12 months between individuals who were and were 
not on hydroxyurea, and between individuals who were and were not adherent to 
hydroxyurea. For those with a current prescription for hydroxyurea, the majority 
(66.5%) were receiving hydroxyurea for recurrent pain episodes or acute chest 
syndrome (19.9%). Hydroxyurea was discontinued because of patient/family 
preference (34.5%), chronic transfusions (31.1%), and side effects (24.1%). 
Patients prescribed hydroxyurea for empiric use (n=21) had fewer 
hospitalizations for pain, ED visits, and severe pain interfering with daily 
activities. The major barriers to hydroxyurea use, from the perspective of 
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individuals with SCD or their caregivers, were 1) forgetting to take the medicine 
(19.4%), 2) worried about side effects (16.4%), and 3) lack of knowledge about 
hydroxyurea (13.6%). Fewer young adults (49.1%) and adults (50.0%) had 
primary care providers than children (78.1%) and adolescents (65.2%). 
Conclusions: Barriers to hydroxyurea use persist with emerging solutions to 
alleviate these barriers. For this sample, while hydroxyurea prescription rates by 
sickle cell specialists were similar to what has been seen in some other studies, 
neither hydroxyurea use nor adherence were associated with decreased 
frequency of hospitalizations for pain, ED visits, and severe acute pain episodes 
in the previous 12 months. Future studies need to evaluate hydroxyurea 
prescription patterns, duration on hydroxyurea, and adherence to hydroxyurea. 
Healthcare providers are recommended to prescribe hydroxyurea for eligible 
individuals who may benefit from it, such as those HgbSS or HgbS-β0 
thalassemia genotype, and prescribe for empiric use to minimize complications. 
Provider and patient education about hydroxyurea could reduce common barriers 
experienced by individuals with SCD. It is important to customize educational 
resources to specific concerns for different age groups. Individuals 18 years and 
older with SCD have been documented with more ED visits and hospitalizations 
due to pain, most likely because they did not have a primary care provider and 
an adult hematologist with expertise in SCD. Future studies need to evaluate 
whether primary care providers who receive SCD education may promote 
hydroxyurea use and adherence. Dedicating time and resources for shared 
 
 viii 
decision making between providers and patients/families can address concerns 
about hydroxyurea and increase patient/family confidence when deciding about 
hydroxyurea. As more disease-modifying therapies become available for 
individuals with SCD, strategies for shared decision making facilitate 
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Sickle cell disease (SCD) is a genetically inherited blood disorder that 
affects the hemoglobin protein of red blood cells (Piel, et al, 2017). In America, 
about 100,000 people have SCD, and about 1 in every 365 African-American 
infants are born with SCD (CDC, 2020). SCD is caused by a mutation in the β-
hemoglobin gene that leads to more HgbS β-globin chains produced instead of 
normal HgbA β-globin chains. This substitution results in sickle cell genotypes 
such as HgbSS, HgbS-β0 thalassemia, HgbSC, and HgbS-β+ thalassemia with 
varying levels of disease severity (Ballas, et al, 2012). Individuals with the 
heterozygous HgbAS genotype, also known as sickle cell trait, are more 
protected in both morbidity and mortality against malaria (Taylor, et al, 2012). 
 The sickling of red blood cells and poor oxygen delivery from HgbSS 
polymerization leads to a variety of pathophysiological symptoms such as vaso-
occlusion, ischemia, inflammation, oxidative stress, hemolytic anemia, hypoxia, 
and hypercoagulability (Chakravorty, et al, 2015; Piel, et al, 2017). Clinically, 
SCD can cause severe pain associated with vaso-occlusive episodes (VOE), 
acute chest syndrome from intrapulmonary ischemia and infarction, bacterial 
sepsis from hyposplenism, splenic sequestration from obstructed blood flow out 
of the spleen, and ischemic strokes and silent infarcts from obstructed blood flow 
within the brain (Chakrovorty, et al, 2015; Piel, et al, 2017). 
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 Addressing this chronic disease requires lifelong management. Newborn 
screening for SCD allows for early diagnosis and intervention (Quinn, 2013). The 
National Heart, Lung, and Blood Institute (NHLBI) recommends that children with 
SCD be vaccinated against streptococcus pneumoniae and take oral penicillin 
until age five to minimize infection risk, and receive screening for renal disease, 
hypertension, and retinopathy (National Heart Lung, and Blood Institute, 2014). 
For stroke risk screening, an expert panel report recommends transcranial 
doppler (TCD) imaging of intracranial blood vessels until the age of 16 (National 
Heart Lung, and Blood Institute, 2014). In adulthood, blood transfusions are used 
to reduce the risk of stroke and acute chest syndrome (Chakravorty, et al, 2015). 
Curative treatment may be possible for certain individuals with SCD through stem 
cell and marrow transplantation as well as gene therapy, all still at various 
research stages (Fitzhugh, et al, 2017; Krishnamurti, et al, 2019). 
 Recurrent and repetitive VOEs may lead to frequent healthcare visits that 
negatively affect the quality of life for children and adults with SCD. Mild pain is 
typically managed at home with non-steroidal anti-inflammatory drugs (NSAIDs) 
like acetaminophen and ibuprofen (Jerrell, et al, 2011; National Heart Lung, and 
Blood Institute, 2014). Severe VOEs may lead to frequent emergency 
department (ED) visits and hospital admissions for pain (Tanabe, et al, 2012), 
where pain could be treated with stronger opioids (National Heart Lung, and 
Blood Institute, 2014; Muslu, et al, 2020). Patients with SCD unfortunately face 
stigma and discrimination when seeking acute pain relief in the ED. For example, 
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reports have indicated that individuals with SCD received delayed and improper 
treatment of pain, had their pain doubted by healthcare providers, were 
perceived as “drug seekers”, and were not included in the decision-making 
process of their care (Jenerette, et al, 2014; Haywood, et al, 2014; Bulgin, et al, 
2018; Sinha, et al, 2019; Kanter, et al, 2020). This disparity is further amplified by 
observations that African Americans with SCD, despite having higher priority 
triage ratings and higher pain levels, waited 50% longer in the ED before being 
seen by a provider than African Americans with long bone fractures (Haywood, et 
al, 2013). They are also less likely to have their pain believed or be offered opioid 
treatment than African Americans with cancer (Masese, et al, 2019; Dyal, et al, 
2021). Thus, African Americans with SCD suffer from a compounded effect of 
racial bias by the healthcare system and racially-affiliated disease bias when 
seeking acute pain care. 
 Long-term management continues to be challenging for individuals with 
SCD. Thus, newer therapies that reduce complications and delay progression of 
SCD are being studied and introduced. These new disease-modifying therapies 
include oxygen affinity agents (Howard, et al, 2019; Vichinsky, et al, 2019), fetal 
hemoglobin inducers (Molokie, et al, 2017), anti-inflammatory agents (Field, et al, 
2017; Field, et al, 2017; Hoppe, et al, 2017; Daak, et al, 2018), anti-platelet 
agents (Hsu, et al, 2018), and anti-adhesion agents (Ataga, et al, 2017). Current 
disease-modifying therapies include hydroxyurea (Wang, et al, 2011; Yates, et al, 
2013; Lebensburger, et al, 2015; McGann, et al, 2015), red blood cell 
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transfusions (Alvarez, et al, 2013; DeBaun, et al, 2014), and L-glutamine 
(Niihara, et al, 2018; Quinn, 2018). 
Hydroxyurea has been FDA approved since 1998 as a disease-modifying 
therapy for SCD (Ault, 1998). The NHLBI recommends that all individuals with 
HgbSS or HgbS-β0 thalassemia be offered hydroxyurea, beginning at the age of 
nine months (National Heart Lung, and Blood Institute, 2014). Further eligibility 
criteria from the NHLBI evidence-based guidelines include experiencing three or 
more sickle cell-related moderate to severe pain episodes in a 12-month period 
(National Heart Lung, and Blood Institute, 2014).  
 Multiple studies worldwide have demonstrated the benefits of hydroxyurea 
for the management of SCD (Wang, et al, 2011; Lobo, et al, 2013; Luchtman-
Jones, et al, 2016; Rigano, et al, 2018; Tshilolo, et al, 2019), including its safety 
for long-term use (Steinberg, et al, 2010). However, perceived barriers to 
hydroxyurea use hinder full adherence and promotion of the medication for 
individuals with SCD. Barriers include dislike of taking medications, lack of 
knowledge about hydroxyurea, doubt about its effectiveness, forgetfulness, 
payment of medication, getting refills on time, and concerns about potential and 
experienced side effects (Haywood, et al, 2011; Badawy, et al, 2017; Sinha, et al, 
2018; Hodges, et al, 2020). The most common side effects experienced by those 
on hydroxyurea were hyperpigmentation of the skin or nails, hair loss, and 
gastrointestinal discomfort (McGann, et al, 2015). Because of its origin as a 
chemotherapy drug (Kennedy, 1972), there has also been concerns, not 
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supported by current research, that hydroxyurea use could lead to increased risk 
of leukemia (Bjorkholm, et al, 2011; Castro, et al, 2014; Algiraigri, et al, 2014).  
Many studies support the benefits of hydroxyurea, but information 
regarding the barriers to its use remain limited. Study samples are often small, 
conducted with limited age groups, or conducted at a single site (Haywood, et al, 





The purpose of this study was to evaluate reasons for hydroxyurea use, 
from the perspectives of providers, adults with SCD, and parents/caregivers of 
children with SCD, as well as perceived barriers to its use. We examined 
indications and reasons for being “on hydroxyurea,” defined by patients as 
currently taking hydroxyurea, and reported on pain frequency, perceptions of 
barriers, hydroxyurea adherence, and health care access for patients with SCD 






We conducted a cross sectional analysis of data collected within the 
Pacific Sickle Cell Regional Collaborative (PSCRC), a consortium of nine 
western U.S. states. The study was approved by the Institutional Review Boards 
(IRB) of the participating sites. Parents/caregivers of children with SCD less than 
18 years and adults with SCD 18 years and older completed a brief survey about 
hydroxyurea use, indications, side effects, pain frequency, number of ED and 
hospital admissions per year, and individual and family perceptions of barriers to 
hydroxyurea use. Participants completed follow-up surveys, but the current 
analysis includes only baseline data. Data collection occurred between February 
2016 and May 2018.  
 
Setting 
This study was conducted by the PSCRC, a consortium funded by the 
Health Resources and Services Administration. The PSCRC consists of three 
California centers – University of California, San Francisco (UCSF) Benioff 
Children’s Hospital Oakland Northern California Comprehensive Sickle Cell 
Center; University of California, Davis; and the Center for Inherited Blood 
Disorders Orange County. The six other PSCRC sites were Providence Hospital 
in Anchorage, Alaska; University of Arizona Cancer Center in Tucson; St. Luke’s 
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Mountain States Tumor Institute in Boise, Idaho; Children’s Specialty Center in 
Las Vegas, Nevada; Oregon Health and Sciences University in Portland; and 
Seattle Children’s Hospital in Washington. 
 
Sample 
Individuals were eligible if they 1) had a confirmed diagnosis of SCD, 2) 
were followed at one of the PSCRC sites between February 2016 to May 2018, 
and 3) were eligible for hydroxyurea therapy according to the National Heart, 
Lung and Blood Institute evidence-based guidelines (2014). 
 
Recruitment, Screening, & Consenting 
Sickle cell center staff identified eligible individuals/families and described 
the study to them during their regular clinic visits. Pamphlets describing the study 
were also available in clinic and mailed to eligible individuals/families, who were 
then contacted by study personnel directly to enroll. The study was described to 
potential participants by the study personnel in a private area of the clinic or day 
hospital. Potential participants could obtain input from family members and other 
individuals before signing the consent form. Study personnel obtaining consent 
answered questions from potential participants and asked them open-ended 
questions regarding the research to assess their understanding of the research. 
Areas of potential misunderstanding or confusion were probed to ensure that the 




Data Collection Procedures 
At the time of enrollment, and annually, adult patients 18 years and older 
and parents/caregivers of children less than 18 years completed a brief survey 
with information on demographics, pain frequency, health care insurance, and 
primary care providers. Adults with SCD or parents/caregivers of children with 
SCD also completed another brief survey at each clinic visit from February 2016 
to May 2018 with their experiences with hydroxyurea, including any concerns 
about hydroxyurea, side effects, and other barriers. Healthcare providers 
provided information on hydroxyurea and lab values for each clinic visit. 
 Data were collected by research staff through iPad on the hospital 
network, clinic desktop, or paper-based form and entered into a secure REDCap 
database housed at UCSF. 
 
Data Analyses 
Data were transferred from the REDCap database into SPSS for analysis 
(version 27, Chicago, IL). Descriptive statistics (frequencies, percent, means, 
standard deviations) were used to characterize the study participants by their 
demographics (i.e. age, sex, ethnicity, number of people in household, annual 
household income, highest education of head of household), sickle cell disease 
Hgb genotype, and site of service. Independent-Samples Mann-Whitney U Test 
with a two-sided significance level (α=0.05) was performed to evaluate 
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differences in proportions of hospitalizations for pain, ED visits for pain, and 
severe pain interfering with daily activities in the previous 12 months between 
patients on hydroxyurea and patients not on hydroxyurea. Descriptive statistics 
(frequencies, percent) were used to report on pain frequency, hydroxyurea 
indications, adherence to hydroxyurea, health care access, and barriers to 






Patients included 1) children (n=178; 6.7 ± 3.4 years), 2) adolescents 
(n=66; 15.0 ± 1.4 years), 3) young adults (n=57; 21.4 ± 2.6 years), and 4) adults 
(n=112; 39.2 ± 10.6 years). Adults 18 years and older completed their own 
surveys and parents/caregivers completed the surveys for their child(ren). The 
majority were predominantly female (51.6%) and African American (93.2%). The 
most frequent genotype was HgbSS (74.1%). The majority (68.8%) were 
followed in three different California medical centers; while the other patients 
(31.2%) were followed in other Pacific Western States (Alaska, Arizona, Idaho, 










Children (≤12 years) 
Mean ± SD 
 
Adolescents (13-17 years) 
Mean ± SD 
 
 Young Adults (18-25 years) 
Mean ± SD 
 
Adults (≥26 years)  




 6.7 ± 3.4 
 
66 (16.0) 
15.0 ± 1.4 
 
57 (13.8) 
21.4 ± 2.6 
 
112 (27.1) 





















Other (HgbS-β+ Thal, etc.) 
 
306 (74.1) 




Site of Service 
California 





Note. Responses were reported by adults with SCD or parents/caregivers of children with SCD. 
 
The majority (43.8%) reported annual household incomes of <$30,000. 
More than half (61.5%) of the head of households were high school graduates 
(Table 2).  
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Highest Education Completed by Head of 
Household   
     <High School Graduate 
     ≥High School Graduate 







Note. Responses were reported by adults with SCD or parents/caregivers of children with SCD. 
 
Adolescents (28.8%) had more frequent pain episodes, severe enough to 
require hospitalization, in the previous 12 months compared to the other age 
groups. Adults had more frequent ED visits (37.5%) and severe pain that 































































































































































The majority of children (65.2%), adolescents (62.1%), and young adults 
(54.4%) indicated that they were on hydroxyurea. Less than half of the adults 
(39.3%) reported that they were taking hydroxyurea (Table 4). 





































Note. Responses were reported by adults with SCD or parents/caregivers of children with SCD. 
1 On hydroxyurea -- patients currently taking hydroxyurea  
 
The majority of patients with HgbSS (65.5%) or HgbS-β0 thalassemia 
(7.3%) genotype were adherent to hydroxyurea. There were also patients not 
taking hydroxyurea who had HgbSS (63.6%) or HgbS-β0 thalassemia (4.9%) 
genotype (Table 5). 
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Table 5. Hydroxyurea Use and Adherence (by Genotype) 
 


















































Note. Responses were reported by adults with SCD or parents/caregivers of children with SCD.  
1 On hydroxyurea -- patients currently taking hydroxyurea  
2 Adherent -- patients taking hydroxyurea daily in the previous two days  
 
 There was no significant difference between patients on hydroxyurea and 
those not on hydroxyurea in frequency of hospitalizations for pain (19.0% vs. 
19.1%), respectively. Similarly, there were no significant differences between 
patients on hydroxyurea and those not on hydroxyurea in frequency of ED visits 
(24.6% vs. 27.2%) or severe acute pain episodes that kept patients from doing 























Hospitalizations for Pain 
<4 Previous 12 Months 















ED Visits for Pain 
<4 Previous 12 Months 















Severe Pain Interfering Daily 
Activities  
<4 Episodes Previous 12 
Months 





















Note. Responses were reported by adults with SCD or parents/caregivers of children with SCD. 
1On hydroxyurea defined by patients as currently taking hydroxyurea 
Independent-Samples Mann-Whitney U Test with a two-sided level of significance (α=0.05) was 
used to compare pain frequency percentages between patients on hydroxyurea and patients not 
on hydroxyurea. 
 
There were no significant differences between those who were adherent 
and those who were not adherent in pain-related hospitalizations (79.1% vs. 
86.8%, <4 in the previous 12 months), ED visits (76.5% vs. 68.4%, <4 in the 
previous 12 months), or severe pain interfering with daily activities (63.1% vs. 
60.5%, <4 in the previous 12 months), respectively. However, patients who were 
adherent to hydroxyurea had ≥4 pain episodes severe enough to require 
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hospitalization (20.9%), ≥4 pain-related ED visits (23.5%), or ≥4 severe pain 
episodes interfering with daily activities (35.8%) (Table 7).   
Table 7. Pain Frequency and Adherence to Hydroxyurea   
 









Hospitalizations for Pain 
<4 Previous 12 Months 









ED Visits for Pain 
<4 Previous 12 Months 
≥4 Previous 12 Months 
 
Severe Pain Interfering Daily 
Activities  
<4 Episodes Previous 12 Months 





















Note. Responses were reported by adults with SCD or parents/caregivers of children with SCD. 
1 Adherent -- patients taking hydroxyurea daily in the previous two days 
 
Healthcare providers reported that the majority (66.5%) of individuals with 
SCD who were prescribed hydroxyurea were receiving hydroxyurea for recurrent 
pain episodes or acute chest syndrome (19.9%). For children and adults not on 
hydroxyurea, providers reported that it was not indicated (34.7%), the 
patient/family was not interested (22.7%), it was discontinued (16.5%), the 
patient was on chronic transfusion therapy (14.2%), or it had not been introduced 
(10.2%). Providers reported that hydroxyurea was discontinued due to 
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patient/family preference (34.5%), chronic transfusions (31.1%), and side effects 
(24.1%) (Table 8). 






Indications for Hydroxyurea 
Recurrent Pain Episodes 











28 (11.9)  
Reasons NOT on Hydroxyurea 
No Indications 
Hydroxyurea Offered but Not Interested 
Hydroxyurea Discontinued 
Chronic Transfusion 
Hydroxyurea Not Yet Been Introduced 
Concerns About Adherence to Medication 
Concerns About Adherence to Monitoring Protocol 
Other Reason 
(i.e. hemoglobin levels stable, HgbSC or HgbSβ+ 
genotype, didn’t feel well on hydroxyurea, kidney 














Reasons Hydroxyurea Discontinued 
Patient/Family Preference 
Chronic Transfusion 
Side Effects  
Other Reason 








Note. Some responses are >100% due to multiple responses by providers. 
 
Patients who were prescribed hydroxyurea for empiric use (N=21) had 
fewer hospitalizations for pain (4.8%), ED visits (4.8%), and episodes of severe 
pain interfering with daily activities (9.5%) in the previous 12 months. Patients 
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who were prescribed hydroxyurea for complications had more frequent pain-
related hospitalizations (20.4%), ED visits (26.5%), and severe pain (38.9%) 
interfering with daily activities (Table 9). 
Table 9. Indications for Hydroxyurea Prescription and Pain Frequency 
 













Hospitalizations for Pain 
<4 Previous 12 Months 








ED Visits for Pain 
<4 Previous 12 Months 
≥4 Previous 12 Months 
 
Severe Pain Interfering Daily 
Activities  
<4 Episodes Previous 12 
Months 


























Note. Responses for indication for hydroxyurea were provided by providers; responses for pain 
frequency were reported by adults with SCD or parents/caregivers of children with SCD. 
1 Complications -- recurrent pain episodes, acute chest syndrome, neurologic disease, etc. 
 
More than half (52.2%) of patients 18 years and older and 
parents/caregivers of children under 18 who were on hydroxyurea reported no 
barriers to hydroxyurea use. Of those taking hydroxyurea who experienced 
barriers, the most common barrier was forgetting to take the medicine (19.4%), 
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followed by being worried about side effects (16.4%). Having difficulty taking the 
medicine at the right time (5.2%) was also cited as a barrier. The majority 
(42.0%) who were not on hydroxyurea reported that their doctors did not 
recommend it. Those not on hydroxyurea also reported that they were worried 
about side effects (19.1%), did not know enough about the medicine (13.6%), or 
were not interested in taking another medicine (9.9%). Some (9.9%) who were 
not on hydroxyurea reported no barriers to hydroxyurea use. Others had tried 
hydroxyurea but felt that it did not work (9.3%); few had heard “scary” things 





Table 10. Barriers to Hydroxyurea (by Hydroxyurea Use) 
















121 (52.2) 16 (9.9) 
 
Doctor Did Not Recommend It 
 
-- 68 (42.0) 



























Worried About Side Effects 













Did Not Like to Think About Having 














Heard Scary Things About This 
Medicine 
(i.e. cancer, not being able to have 











Table 10 continued. Barriers to Hydroxyurea (by Hydroxyurea Use) 















(i.e. not liking frequent clinic visits, 
other things were more important 
than taking this medicine, having 
mild SCD, pain was not severe 
enough, believed it wasn’t 
necessary, don’t want to take, 
pharmacy doesn’t carry liquid form, 
stomach issues, needed refill, ran 
out of medication, pregnancy, plan 







Note. Some responses are >100% due to multiple responses by adults with SCD or 
parents/caregivers of children with SCD. 
1 On hydroxyurea -- patients currently taking hydroxyurea 
 
There were 111 patients who were adherent to hydroxyurea, 70.3% of 
whom experienced barriers. The most common barriers to hydroxyurea use in 
children included being worried about side effects (13.5%) and other barriers 
(15.2%), including not liking frequent clinic visits, stomach issues, needing 
medication refills, health insurance issues, and the pharmacy not carrying the 
liquid form of the medication. The most common barriers in adolescents included 
forgetting to take the medicine (13.6%), followed by being worried about side 
effects (12.1%). In young adults, forgetting to take the medicine (26.3%) and 
being worried about side effects (17.5%) were most common. Similarly, in adults, 
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the most common barriers were being worried about side effects (24.1%) and 


































15 (8.4) 5 (7.6) 4 (7.0) 8 (7.1) 
Not Interested 
  
4 (2.2) 2 (3.0) 5 (8.8) 8 (7.1) 
Hard to Take 
at the Right 
Time 
 
3 (1.7) 3 (4.5) 3 (5.3) 5 (4.5) 
Forget to Take 
the Medicine 
 








5 (2.8) 1 (1.5) 3 (5.3) 3 (2.7) 






1 (0.6) 2 (3.0) 5 (8.8) 4 (3.6) 
Tried It and Did 
Not Work 
 




   
























Other Barrier3  27 (15.2) 6 (9.0) 9 (15.9) 17 (15.2) 
 
1 Side effects -- cancer, hair loss, fingernail discoloration, nausea/dizziness 
2 Scary things heard about this medicine -- cancer, not being able to have children, hair loss, 
infection 
3 Other barriers -- not liking frequent clinic visits, other things were more important than taking this 
medicine, having mild SCD, pain was not severe enough, believed it wasn’t necessary, don’t want 
to take, pharmacy doesn’t carry liquid form, stomach issues, needed refill, ran out of medication, 
pregnancy, plan to start family, insurance, swallowing issues 
 
The majority of children (65.8%), adolescents (59.1%), young adults 
(59.6%), and adults (81.2%) had public health insurance. A majority of children 
(78.1%) and adolescents (65.2%) also had a primary care provider. Fewer young 











































































































Note. Some responses are >100% due to multiple responses by adults with SCD or 
parents/caregivers of children with SCD. 
1 Public health insurance -- Medicare, Medicaid/Medi-Cal 
2 Other government-sponsored health insurance – State Children’s Health Insurance Program  
(SCHIP), Military Health Care (Tricare/VA/CHAMP-VA), state-sponsored health plan 






This is the largest sample size to date that evaluates barriers to 
hydroxyurea use and provider behaviors in prescribing the medication for both 
patients with SCD under 18 years old, reported by their parents/caregivers, and 
patients 18 years and older. Over half of the sample reported that they were 
taking hydroxyurea. Specifically, while a majority of children, adolescents, and 
young adults were on hydroxyurea, less than half of the adults, 26 years old and 
older, were on hydroxyurea. This observation aligns with the findings of Singh 
and colleagues (2018), where 65% of participants 18 to 30 years old and 41% of 
participants 31 to 67 years old were currently taking hydroxyurea. Explanations 
for the decreased percentage of older participants taking hydroxyurea included 
doubt about the safety and efficacy of the medication, worries about side effects 
and complications from long-term use, hesitance towards taking additional 
medication, and concerns about its original use as a chemotherapy drug (Singh, 
et al, 2018). Education on hydroxyurea that addresses the concerns and worries 
of adults 26 years old and older could encourage hydroxyurea use in this age 
group. 
According to the National Heart, Lung and Blood Institute evidence-based 
guidelines (2014), because individuals with HgbSS or HgbS-β0 thalassemia 
display similar clinical symptoms of increased frequency of pain episodes, it is 
strongly advised that these individuals take hydroxyurea to reduce their 
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frequency of pain episodes that interferes with their daily activities. While the 
majority were on hydroxyurea, some patients were not receiving hydroxyurea 
who could benefit from it. Interestingly, no significant differences were found in 
the frequency of hospitalizations for acute pain episodes, ED visits due to pain, 
or severe pain that kept individuals from doing daily activities between those who 
were and were not on hydroxyurea. These findings are inconsistent with the 
study by Quarmyne and colleagues (2017), who reported that patients had 
significantly less frequent ED and hospitalization visits for acute pain episodes 
two years after initiating hydroxyurea compared to the two years before. The 
differences may be explained by variables not captured in this data set, such as 
the duration of hydroxyurea use and variations of dosages, which could affect the 
pain frequency. 
The findings in this study indicated that in patients taking hydroxyurea, 
only 65.5% of those with HgbSS and 7.3% of those with HgbS-β0 thalassemia 
were adherent to taking hydroxyurea. However, there were no differences in pain 
frequency between those who were adherent and were not adherent to 
hydroxyurea. It is possible that the lack of adherence may be related to perceived 
barriers. Future studies are needed to explore factors that could explain 
differences in those who were and were not adherent to hydroxyurea, such as 
side effects, concerns, or barriers.  
Individuals who were prescribed hydroxyurea for complications had more 
frequent pain episodes requiring hospitalizations, ED visits, and interfering with 
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daily activities compared to individuals who were prescribed it for empiric use. 
These findings are consistent with a report by Thornburg and colleagues (2012), 
who evaluated the effects of hydroxyurea on children (9-18 months) with HgbSS 
or HgbS-β0 thalassemia genotype and found that those who took hydroxyurea 
had less sickle cell-related complications, pain episodes, dactylitis episodes, 
hospitalizations for pain, and transfusions. They also noted that children who 
were asymptomatic and were taking hydroxyurea had fewer episodes of 
dactylitis, hospitalizations for pain, and transfusions. Thus, SCD-related 
complications may be prevented if it is prescribed for empiric use in young 
children. Only 9.3% in this study were prescribed hydroxyurea for empiric use 
and age analyses were not possible. Older children, adolescents, young adults, 
and adults may benefit if they were prescribed it for empiric use. Further studies 
with larger sample sizes are needed to evaluate whether there are differences by 
age when hydroxyurea is prescribed for empiric use. 
This study found that the most common barrier to hydroxyurea use is 
forgetfulness, which others have also reported (Badawy, et al, 2017; Jose, et al, 
2019; Hodges, et al, 2020). Forgetfulness may be associated with neurocognitive 
deficits, including memory impairment and decrease in executive functioning that 
had been demonstrated in different age groups and infarct status by other reports 
(Feliu, et al, 2011; Prussien, et al, 2019; Martin, et al, 2020). Future studies are 
needed to examine whether neurocognition is associated with barriers and 
adherence to hydroxyurea use. Some studies have reported that forgetfulness is 
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an important barrier in medication adherence for other chronic conditions 
(Aggarwal, et al, 2015; Hargis, et al, 2018; Alshehri, et al, 2020). Healthcare 
providers may consider use of strategies to decrease forgetfulness, such as 
adherence mobile apps (Creary, et al, 2014; Badawy, et al, 2016; Makubi, et al, 
2016; Inoue, et al, 2016; Leonard, et al, 2017; Curtis, et al, 2019) and automated 
text message reminders (Estepp, et al, 2014; Pernell, et al, 2017). Community 
health workers have also been utilized to facilitate adherence to hydroxyurea 
(Green, et al, 2017).  
Another major barrier reported by individuals with SCD was “worries about 
side effects.” This finding is consistent with a study by Haywood and colleagues 
(2011), where patients who did not use, were formerly using, or were currently 
using hydroxyurea were concerned about its safety, impact on ability to 
reproduce, and carcinogenic side effects. Oyeku and colleagues (2013) also 
found that parents were worried about the carcinogenic, teratogenic, and 
reproductive side effects of hydroxyurea. Adolescents and adults with SCD also 
expressed concerns about cancer risk, hair loss, nail discoloration, and other 
side effects (Hodges, et al, 2020). Smith and colleagues (2019) found a 158.8% 
increase in the number of patients initiating hydroxyurea after discussing side 
effects, risks, and concerns on teratogenicity, oncogenicity, hair loss, and risk of 
HIV infection with their healthcare providers. Therefore, it is important for 
healthcare providers to address patient and family concerns and risks of side 
effects to minimize barriers to hydroxyurea use. 
 
32 
An important factor for individuals not taking hydroxyurea is the lack of 
knowledge about hydroxyurea. In this study sample, 13.6% of individuals not on 
hydroxyurea reported that they did not know enough about the medicine, a 
barrier consistent with other studies. For example, Haywood and colleagues 
(2011) found that in 94 adults with SCD, some were inquiring whether 
“hydroxyurea is a blood thinner” and “have never heard about it” (Haywood, et al, 
p.2-3). On the other hand, Sinha and colleagues (2018) found that in 95 adults 
with SCD, those who could explain the mechanism of action for hydroxyurea and 
its benefits were more likely to be taking hydroxyurea and had a more positive 
experience. Therefore, patient education to increase knowledge on hydroxyurea 
may minimize this barrier. 
Interestingly, there were many individuals whose providers did not 
recommend hydroxyurea because it was not indicated. There were individuals 
with HgbSS or HgbS-β0 thalassemia genotype who were not prescribed 
hydroxyurea who may benefit as recommended in the National Heart, Lung and 
Blood Institute evidence-based guidelines (2014). Cabana and colleagues (2019) 
reported that provider hesitancy in prescribing hydroxyurea, despite having 
familiarity with the 2014 NHLBI Sickle Cell Disease guidelines, may be due to 
provider concerns about patient adherence to the medication. Furthermore, 
sickle cell disease providers also expressed a lack of self-efficacy, particularly in 
identifying which patients may benefit from hydroxyurea, prescribing the correct 
dose, recognizing side effects, and discussing risks of the medication with 
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patients/families (Cabana, et al, 2019). Thus, strengthening provider 
understanding and confidence in implementing the 2014 NHLBI Sickle Cell 
Disease guidelines may help increase the number of recommendations to 
individuals with SCD who are eligible for hydroxyurea therapy. 
In the present study, there were individuals who were on hydroxyurea, but 
preferred not to continue. Information on the patient rationale for discontinuing 
was not collected. Some studies report that patients discontinued hydroxyurea 
because they were experiencing side effects, not feeling that it was working to 
decrease pain severity and frequency, not liking how it made them feel, having 
difficulty adhering to hydroxyurea monitoring protocol, or were considering 
pregnancy (Haywood, et al, 2011; Hodges, et al, 2020). Some of these concerns 
could have been addressed through hydroxyurea education to provide realistic 
expectations on the treatment regimen and tools to support adherence. It is also 
possible that patients who discontinued hydroxyurea were offered other novel 
disease-modifying therapies. Although novel treatments could provide alternative 
benefits for individuals with SCD, since barriers to hydroxyurea use and 
prescription still exist, what is learned about hydroxyurea could also be 
informative in addressing similar barriers with these other medications. 
The lack of knowledge about hydroxyurea, fear of its side effects, and 
several other barriers experienced by individuals with SCD who are eligible to 
take hydroxyurea can be addressed through shared decision making between 
the provider and patient/family. Shared decision making is an opportunity for the 
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provider and patient/family to meet and discuss the purpose, benefits, 
mechanism of action, and side effects of hydroxyurea, as well as address any 
questions or concerns. In a study performed by Pecker and colleagues (2018), 
children with SCD and their families were invited to an education session on 
hydroxyurea in the outpatient hematology following an ED visit or during 
hospitalization. At the session, a hematologist reviewed the handbook on starting 
hydroxyurea with the participants, showed a video of patients discussing their 
experiences with hydroxyurea, and then directly offered hydroxyurea. 
Subsequently, 55% of participants were prescribed and 83% continued taking 
hydroxyurea after a 49-week follow-up. Pecker’s method was particularly 
effective in starting and keeping individuals on hydroxyurea because it was 
introduced shortly after the individual experienced the painful complications of 
the disease. Crosby and colleagues (2019) created a shared decision making 
toolkit consisting of an educational brochure given to parents/caregivers prior to a 
clinic visit. Parents/caregivers also viewed parent video narratives about 
experiences with hydroxyurea and received an after-visit booklet on hydroxyurea. 
Future studies are needed to determine whether this educational intervention will 
minimize barriers to hydroxyurea knowledge. Both Pecker and Crosby offered 
potential solutions to encourage the start of an informative conversation between 
the provider and patient/family. Not only does shared decision making encourage 
providers to build their understanding and confidence in explaining and 
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prescribing hydroxyurea, but it also educates the individuals about their options 
and provides them with tools to make informed decisions about their care. 
The majority of individuals in our study had private, government 
sponsored, and/or public health insurance. Some, however, expressed difficulties 
with obtaining medications due to their pharmacy not having the liquid 
formulation, not having prescription refills, or insurance reimbursement issues. 
Badawy and colleagues (2017) also reported that 33% of adolescents and young 
adults had issues with getting refills and insurance coverage. Future studies are 
needed to evaluate whether health insurance is a barrier to hydroxyurea. 
While a majority of children and adolescents had a primary care provider, 
fewer young adults and adults reported that they had a primary care provider, 
despite the ED and hospital not being ideal locations to manage SCD-related 
pain and complications. The lack of a primary care provider home for older 
individuals with SCD is alarming since this data set shows a continued increase 
in ED visits for SCD-related pain as individuals grow older. This trend was also 
found in a study conducted by Blinder and colleagues (2015), where a state 
Medicaid data search of 3208 patients for ED visits for pain showed an increase 
in the mean ED visits per quarter from 0.76 to 2.29 in patients ages 16-24, and to 
2.9 ED visits in patients at 36 years old. This phenomenon aligns biologically with 
the increased acute pain episodes and the onset of chronic pain from 13-18 
years old (Brandow, et al, 2018), and the potential for acute pain to transition to 
persistent, chronic pain in adulthood, further leading to additional healthcare 
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utilization (Matthie, et al, 2019). Considering that there is a decrease of 
individuals over 18 years old who reported that they had a primary care provider 
in this data set, connecting patients with a primary care provider when they 
transition to adulthood could decrease their need to utilize the ED frequently for 
their pain management. Mainous III and colleagues (2019) analyzed EMR data 
for trends in healthcare utilization and having a primary care provider and 
hematologist. It observed that adult patients 21 years and older who were 
receiving shared care from both a primary care provider and a hematologist had 
decreased hospitalizations for severe pain. Similarly, Raphael and colleagues 
(2013) conducted a study with parents of children ages 1-17 years old, where 
participants were asked about their perception of access to primary care and 
healthcare utilization. That study concluded that children who received 
comprehensive care had lower rates of ED visits and hospitalizations for pain. 
Future studies are needed to evaluate whether primary care providers could 
promote hydroxyurea uptake and adherence, and reduce barriers to hydroxyurea 
use. 
Although this study did not investigate the individuals’ reasons for not 
having a primary care provider, this observation might be explained by a patient 
focus group discussion study conducted by AlJuburi and colleagues (2012). 
Patients aged 9-56 years old expressed barriers to relying on a primary care 
provider for SCD care, including long waiting times to see a primary care 
provider, limited provider knowledge about SCD, limited provider knowledge 
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about the standard and guidelines for disease management, lack of 
communication between primary care providers and specialists, and lack of 
follow-up after an ED visit or hospitalization for severe pain. Many primary care 
providers in studies conducted by Whiteman and colleagues (2015) and Lunyera 
and colleagues (2017) echoed a lack of comfort in providing SCD care, a lack of 
awareness in the 2014 NHLBI Sickle Cell Disease guidelines, and limited 
communications with specialists. To address these barriers, Lunyera and 
colleagues (2017) created a mobile app to allow primary care providers to access 
SCD guidelines and communicate with SCD specialists, with 51% being 
comfortable with accessing the guidelines and 38% being comfortable with 
communicating with the specialists. Further studies are needed to evaluate 
methods to increase primary care provider knowledge in the 2014 NHLBI Sickle 




Several factors limit the representativeness and generalizability of 
findings. First, despite the large sample size, the sample represented patients 
who were followed in the western United States. Patients followed in other parts 
of the country might experience different barriers, such as health insurance 
coverage, which may influence how interventions should be applied. Second, 
barriers to hydroxyurea may differ depending on whether patients were living in 
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urban or rural areas. For example, differences in access to comprehensive 
healthcare services may affect frequencies of ED visits and hospitalizations for 
pain. Third, the medication start date was not recorded for hydroxyurea, which 
could clarify whether the duration on hydroxyurea impacts the number of ED 
visits and hospitalizations for pain seen in this sample. Fourth, provider reasons 
for not prescribing hydroxyurea was not investigated. Since the 2014 NHLBI 
Sickle Cell Disease guidelines recommends that providers offer hydroxyurea to 
individuals with HgbSS or HgbS-β0 thalassemia genotype, understanding 
provider reasons for not prescribing hydroxyurea could provide context to the 
concerns of providers in hydroxyurea use and facilitate the development of 
education materials to address these concerns. Lastly, this data was collected 
prior to the availability of other new therapies for sickle cell disease. Thus, this 
study did not look into patients’ awareness, level of understanding, and 







Barriers to hydroxyurea use persist with emerging solutions to alleviate 
these barriers. For this sample, while hydroxyurea prescription rates by sickle cell 
specialists were similar to what has been seen in some other studies, neither 
hydroxyurea use nor adherence to hydroxyurea were associated with decreased 
frequency of hospitalizations for pain, ED visits, and severe acute pain episodes 
in the previous 12 months. Healthcare providers are recommended to prescribe 
hydroxyurea for empiric use to minimize complications and hospitalizations for 
pain, ED visits, and severe acute pain episodes that interfere with daily activities. 
Future studies need to evaluate hydroxyurea prescription patterns, duration on 
hydroxyurea, and adherence to hydroxyurea.  
Healthcare providers are recommended to prescribe hydroxyurea for 
eligible individuals who may benefit from it, such as those with HgbSS or HgbS-
β0 thalassemia genotype (2014 NHLBI Sickle Cell Disease guidelines), and 
prescribe for empiric use to minimize complications. When providing hydroxyurea 
education to patients and parents/caregivers, healthcare providers also need to 
discuss patient and parent/caregiver concerns about safety, side effects, worries, 
cognitive function, and other barriers. Furthermore, it is important to customize 
educational resources to specific concerns for different age groups. Future 
studies should evaluate age-focused educational materials that may affect 
hydroxyurea initiation and adherence. 
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There are healthcare providers who lack knowledge of hydroxyurea, which 
is a major barrier to prescription and highlights the need for ongoing healthcare 
provider education. The use of technology, such as webinars, podcasts, and 
various forms of information delivery are increasingly being used and may 
provide an accessible and convenient strategy for providing hydroxyurea 
education to healthcare providers. 
Individuals 18 years and older with SCD have been documented with 
more ED visits and hospitalizations due to pain, most likely because they did not 
have a primary care provider and an adult hematologist with expertise in SCD. 
Future studies need to evaluate whether primary care providers who receive 
SCD education may promote hydroxyurea use and adherence. Well-informed 
providers may be more likely to engage patients in decision making and 
coordinating care with a hematologist, pain specialist, and the ED. 
Dedicating time and resources for shared decision making between 
providers and patients/families can address concerns about hydroxyurea and 
increase patient/family confidence when deciding about hydroxyurea. As more 
disease-modifying therapies become available for individuals with SCD, 
strategies for shared decision making may facilitate standardization and optimize 
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